Search for information about a product,
therapeutic area or event

Media, investors, advocacy organizations and others, please contact us here.

Posters

 Sparsentan in Patients With Prior or Concurrent Immunosuppressive Treatment (IST) for IgA Nephropathy (IgAN): A Case Series 

Posters

 Sparsentan in Pediatric Patients With Rare Proteinuric Kidney Disease: Preliminary Findings From the EPPIK Study 

Posters

 Health-Related Quality of Life in Adult Patients With Focal Segmental Glomerulosclerosis (FSGS): Sparsentan Versus Irbesartan 

Posters FSGS

Outcomes of the DUPLEX Trial in Patients With Genetic Focal Segmental Glomerulosclerosis (gFSGS)

Posters

Pegtibatinase, an Investigational Enzyme Replacement Therapy, for the Treatment of Classical Homocystinuria (HCU): Design of the HARMONY Phase 3 Study

Posters

Latest Results From the COMPOSE®Phase 1/2 Trial for the Treatment of Classical Homocystinuria (HCU) Using Pegtibatinase, a Novel Investigational Enzyme Replacement Therapy

Posters

Association Between Homocysteine and Clinical Outcomes in Patients With Classical Homocystinuria: A Systematic Literature Review

Posters

Clinical Burden of Classical Homocystinuria in the United States: A Retrospective Claims Analysis

Posters

Economic Burden of Classical Homocystinuria in the United States

Posters

Matching-Adjusted Indirect Comparisons of eGFR Slopes in the PROTECT Study with UK RaDaR IgA Nephropathy Population and the Control Arm of NefIgArd

Posters

 The Humanistic Burden of Rare Kidney Diseases: Understanding the Impact of Immunoglobulin A Nephropathy (IgAN) and Focal Segmental Glomerulosclerosis (FSGS) on Patients and Care-Partners Study (HONUS): Results for IgAN and FSGS in Europe

Posters

Sparsentan Has Direct Effects on the Glomerular Capillary Wall to Attentuate Increased Permeability After Exposure to Nephrotic Syndrome Plasma

Posters

Natural History of Idiopathic Nephrotic Syndrome: The UK National RaDaR Idiopathic Nephrotic Syndrome Cohort